67 results on '"Jovani V"'
Search Results
2. AB0898 SAPHO: CLINICAL CHARACTERISTICS OF A SPANISH MULTICENTER REGISTRY
3. P493 Do antiTNF or Ustekinumab trough levels correlate with joint extraintestinal manifestations activity in Inflammatory bowel disease patients?
4. AB0494 ADIPOSITY SEEMS TO NOT INTERFERE WITH THE JAK INHIBITORS RESPONSE IN RHEUMATOID ARTHRITIS: AN EXPLORATORY STUDY
5. AB1219 HOW TO TAILOR THE ANTI-OSTEOPOROSIS TREATMENT IN PATIENTS WITH ADVANCED LIVER DISEASE? VARIATIONS OF RENAL FUNCTION BY CREATININE AND CYSTATIN C
6. POS1574 SAPHO SYNDROME, CLINIC CHARACTERISTICS FROM THE SAPHO-SORCOM COHORT
7. POS0638 SURVIVAL OF BIOSIMILAR ANTI-TNFΑ BLOCKERS COMPARED TO ORIGINATOR MOLECULES IN RHEUMATOLOGY: RESULTS FROM THE BIOBADASER COHORT
8. Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies
9. P424 Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?
10. POS1331 CERTOLIZUMAB PEGOL IN UVEITIS. RETENTION PROBABILITY AND CAUSES OF DISCONTINUATION.
11. POS0907 ASSOCIATION BETWEEN DISEASE ACTIVITY AND DAMAGE IN IDIOPATHIC INFLAMMATORY MYOPATHIES. DIFFERENCES BETWEEN INCIDENT AND PREVALENT CASES
12. AB0907 TREATMENT WITH UPADACINITIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF FIRST PATIENTS OF CLINICAL PRACTICE
13. POS0935 HIGHER 5-YEAR SURVIVAL OF CERTOLIZUMAB PEGOL IN YOUNG WOMEN WITH AXIAL SPONDYLOARTHRITIS. BIOBADASER DATA
14. POS1350 UVEITIS DUE TO IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATED WITH CERTOLIZUMAB PEGOL. MULTICENTER STUDY OF 80 PATIENTS.
15. POS1351 CERTOLIZUMAB PEGOL VS ADALIMUMAB IN THE TREATMENT OF REFRACTORY CYSTOID MACULAR EDEMA DUE TO BEHÇET’S DISEASE. MULTICENTER STUDY.
16. POS0940 FACTORS ASSOCIATED WITH LONG-TERM RETENTION OF TREATMENT WITH GOLIMUMAB IN A LARGE COHORT OF PATIENTS WITH RHEUMATIC DISEASES, WITH UP TO 8 YEARS OF FOLLOW-UP
17. AB0758 Golimumab after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: four-year retention rate in the Spanish BIOBADASER registry
18. Reviewing Disease Activity Indices in Spondyloarthritis From the Sex Perspective: A Systematic Review and Metaanalysis
19. Response to: 'Comparative analysis of synovial inflammation after SARS-CoV-2 infection' by Alivernini et al
20. Acute arthritis following SARS-CoV-2 infection
21. OSTEOPOROSIS AND INSUFFICIENCY RISK FACTORS IN PSORIATIC ARTHRITIS
22. POS1340 MULTICENTER STUDY OF 71 PATIENTS WITH REFRACTORY UVEITIS RELATED TO IMMUNE-MEDIATED INFLAMMATORY DISEASES ON CERTOLIZUMAB PEGOL TREATMENT
23. POS1081 OSTEOPOROSIS AND INSUFFICIENCY RISK FACTORS IN PSORIATIC ARTHRITIS
24. THU0464 USE OF BENZODIAZEPINES AND ANTIDEPRESSANTS IN PATIENTS WHO ATTEND A RHEUMATOLOGY CLINIC
25. THU0311 CERTOLIZUMAB THERAPY IN REFRACTORY UVEITIS DUE TO IMMUNE-MEDIATED INFLAMMATORY DISEASES (IMID). MULTICENTER STUDY OF 39 PATIENTS
26. FRI0504 TOCILIZUMAB IN GRAVES’ ORBITOPATHY. MULTICENTER STUDY OF 48 PATIENTS.
27. THU0414 ORDINARY LIGHT MICROSCOPY IS ABLE TO IDENTIFY MOST CRYSTAL-CONTAINING SYNOVIAL FLUIDS
28. Case series of acute arthritis during COVID-19 admission
29. Y Comment on: Reclassification into very-high cardiovascular risk in psoriatic arthritis as well as axial spondyloarthritis
30. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors
31. PREVALENCE OF BENZODIAZEPINS AND ANTIDEPRESSANTS USE IN PATIENTS WHO ATTEND A RHEUMATOLOGY CLINIC
32. PREVALENCE OF SUBCLINICAL CARDIOVASCULAR DISEASE IN PSORIATIC ARTHRITIS: A MULTICENTER STUDY
33. ORDINARY LIGHT MICROSCOPY IS ABLE TO IDENTIFY MOST CRYSTAL-CONTAINING SYNOVIAL FLUIDS
34. PREVALENCE OF SUBCLINICAL CARDIOVASCULAR DISEASE IN PSORIATIC ARTHRITIS: A MULTICENTRIC STUDY
35. LEISHMANIASIS IN PATIENTSWITH CHRONIC INFLAMMATORY DISEASE TREATED WITH IMMUNOMODULATORS. MULTICENTER ANALYSIS
36. Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology
37. Challenges to conquer from the gender perspective in medicine: The case of spondyloarthritis
38. FRI0607 Long-term and optimization of infliximab in refractory uveitis associated to behÇet disease. multicentre study of 100 patients
39. HOW TO TAILOR THE ANTI-OSTEOPOROSIS TREATMENT IN PATIENTS WITH ADVANCED LIVER DISEASE? VARIATIONS OF RENAL FUNCTION BY CREATININE AND CYSTATIN C.
40. TREATMENT WITH UPADACINITIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF 101 PATIENTS OF CLINICAL PRACTICE.
41. ADIPOSITY SEEMS TO NOT INTERFERE WITH THE JAK INHIBITORS RESPONSE IN RHEUMATOID ARTHRITIS: AN EXPLORATORY STUDY.
42. SAPHO SYNDROME, CLINIC CHARACTERISTICS FROM THE SAPHO-SORCOM COHORT.
43. Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients
44. SAT0311 The Shape of Calcium Pyrophosphate Crystals Determines their Intensity of Birefringence
45. SURVIVAL OF BIOSIMILAR ANTI-TNF? BLOCKERS COMPARED TO ORIGINATOR MOLECULES IN RHEUMATOLOGY: RESULTS FROM THE BIOBADASER COHORT.
46. Anti-TNF- therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients
47. AB0732 Gendered Issues about Spondyloarthritis. Another CASE Yentl's Syndrome?
48. SAT0148 Short and Long-Term Biological Therapy in Refractory Uveitis of Behcet’S Syndrome. Multicenter Study of 108 Patients
49. SAT0149 Biologic Therapy: Switching and Dose Modification in Refractory Uveitis of Behcet’S Syndrome. Multicenter Study of 108 Patients
50. FRI0213 Anti-TNF therapy in refractory uveitis of behcet’s syndrome. A multicenter study of 63 patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.